Current studies demonstrate that gene modulation of dyslipidemia-associated targets (in particular, PCSK9) can have a positive effect not only on the atherosclerotic process but also on the risk of atrial fibrillation (AF). This evidence concerns the gene PCSK9 and atrial fibrillation.